← Leaderboards
Axel T Lehrer
Hawaii Biotech, Inc.
$10,832,675
Attributed
$10,832,675
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2005–23$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$9,733,174 · 4
CDC$1,099,501 · 1
By mechanism
R01$8,359,666 · 2
R43$1,373,508 · 2
U01$1,099,501 · 1
Top collaborators
No co-investigators on record.
Most similar at Hawaii Biotech, Inc.
Same institution · by research overlap
- David E. Clements$13,267,458
- Beth-Ann Coller$10,591,331
Others in their field
Top investigators on “Vaccine Development”
- Lawrence Corey · Fred Hutchinson Cancer Center$718,120,301
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$554,939,981
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$394,383,754
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$392,263,550
- Dennis R. Burton · Scripps Research Institute$312,611,400
Research focus
Vaccine DevelopmentVaccinesImmunogenicViral ProteinsProtein SubunitsRecombinantsNonhuman PrimateDrosophila GenusImmunogenicityMembrane GlycoproteinsPrimatesAdjuvantVirusSafetyEbola VaccinesGlycoproteinsBaseAntibodiesDisease OutbreaksFilovirusBioterrorismInfectionAntigensVirus Diseases
Grant awards (19)
Epidemiology and Immunity to Ebola Virus and Other Emerging Viral Infections in Liberia$200,000
U01 · FY2023 · GH · contact PI
Epidemiology and Immunity to Ebola Virus and Other Emerging Viral Infections in Liberia$200,000
U01 · FY2022 · GH · contact PI
Preclinical Development of a Thermostable Trivalent Filovirus Vaccine$1,211,368
R01 · FY2021 · AI · contact PI
GH19-003, Epidemiology and Immunity to Ebola Virus and Other Emerging Viral Infections in Liberia$199,500
U01 · FY2021 · GH · contact PI
Preclinical Development of a Thermostable Trivalent Filovirus Vaccine$1,203,584
R01 · FY2020 · AI · contact PI
GH19-003, Epidemiology and Immunity to Ebola Virus and Other Emerging Viral Infections in Liberia$1
U01 · FY2020 · GH · contact PI
Preclinical Development of a Thermostable Trivalent Filovirus Vaccine$1,209,712
R01 · FY2019 · AI · contact PI
Epidemiology and Immunity to Ebola Virus and Other Emerging Viral Infections in Liberia$500,000
U01 · FY2019 · GH · contact PI
Preclinical Development of a Thermostable Trivalent Filovirus Vaccine$1,224,098
R01 · FY2018 · AI · contact PI
Defining a Protective Ebola Vaccine in Non-Human Primates$522,686
R01 · FY2018 · AI · contact PI
Preclinical Development of a Thermostable Trivalent Filovirus Vaccine$1,437,310
R01 · FY2017 · AI · contact PI
Defining a Protective Ebola Vaccine in Non-Human Primates$529,083
R01 · FY2017 · AI · contact PI
Defining a Protective Ebola Vaccine in Non-Human Primates$29,340
R01 · FY2017 · AI · contact PI
Defining a Protective Ebola Vaccine in Non-Human Primates$492,487
R01 · FY2016 · AI · contact PI
Defining a Protective Ebola Vaccine in Non-Human Primates$499,998
R01 · FY2015 · AI · contact PI
Development of a Recombinant Subunit Ebola Vaccine$477,131
R43 · FY2008 · AI · contact PI
Development of a Recombinant Subunit Ebola Vaccine$474,207
R43 · FY2007 · AI · contact PI
Recombinant Subunit Vaccine for Tick-Borne Encephalitis$171,926
R43 · FY2005 · AI
Recombinant Subunit Vaccine for Tick-Borne Encephalitis$250,244
R43 · FY2004 · AI